Abiopharma

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

New Form 4 - Enhabit, Inc. Filed: 2025-08-07 AccNo: 0001803737-25-000153 Size: 4 KB

New Form 10-Q - Disc Medicine, Inc. Filed: 2025-08-07 AccNo: 0001816736-25-000007 Size: 9 MB

New Form 4 - Enhabit, Inc. Filed: 2025-08-07 AccNo: 0001803737-25-000152 Size: 4 KB

New Form SCHEDULE 13G - China SXT Pharmaceuticals, Inc. Filed: 2025-08-07 AccNo: 0001213900-25-072835 Size: 6 KB

New Form 8-K - Disc Medicine, Inc. Filed: 2025-08-07 AccNo: 0001816736-25-000006 Size: 509 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 4 - Enhabit, Inc. Filed: 2025-08-07 AccNo: 0001803737-25-000151 Size: 5 KB

New Form 10-Q - Prime Medicine, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038619 Size: 6 MB

New Form 4 - Enhabit, Inc. Filed: 2025-08-07 AccNo: 0001803737-25-000150 Size: 4 KB

New Form 10-Q - Rallybio Corp Filed: 2025-08-07 AccNo: 0001739410-25-000112 Size: 5 MB

New Form 8-K - Prime Medicine, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038617 Size: 232 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 4 - Enhabit, Inc. Filed: 2025-08-07 AccNo: 0001966580-25-000003 Size: 4 KB

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

New Form SCHEDULE 13G - China SXT Pharmaceuticals, Inc. Filed: 2025-08-07 AccNo: 0001213900-25-072832 Size: 6 KB

New Form 8-K - MetaVia Inc. Filed: 2025-08-07 AccNo: 0001558370-25-010658 Size: 429 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits